Stock code: 000963 Stock abbreviation: Huadong Medicine Announcement No.: 2021-076
Huadong Medicine Co., Ltd.The Third Quarterly Report 2021
Important Declaration:
1.The Board of Directors, Board of Supervisors, directors, supervisors and senior management ofHuadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that theinformation presented in this report is authentic, accurate and complete and free of any false records,misleading statements or material omissions, and shall undertake individual and joint legalliabilities.
2.The Company’s legal representative and the officer in charge of accounting, and head ofaccounting department (accounting supervisor) hereby declare and guarantee that the financialstatements in this quarter report are authentic, accurate and complete.
3.Has the third quarterly report been audited?
□ Yes √ No
This report is prepared both in Chinese and English. Should there be any discrepancy between theChinese and English versions, the Chinese version shall prevail.I. Key financial data(I) Key Accounting Data and Financial IndicatorsWhether the Company needs to perform retroactive adjustment or restatement of previous accounting data
□ Yes √ No
The Company and all members of the Board of Directors hereby guarantee that the informationpresented in this report is authentic, accurate and complete and free of any false records,misleading statements or material omissions.
| The current reporting period | Change of the current reporting period over the same period last year | From the beginning of the year to the end of the reporting period | Change from the beginning of the year to the end of the reporting period over the same period last year | |
| Operating revenue (yuan) | 8,748,039,460.66 | -1.04% | 25,927,477,363.27 | 1.67% |
| Net profit attributable to shareholders of listed companies (yuan) | 595,038,254.49 | -9.88% | 1,895,384,579.34 | -20.74% |
| Net profit attributable to shareholders of listed | 568,039,187.19 | -9.00% | 1,762,020,074.37 | -13.24% |
| companies after deducting non-recurring gains/losses (yuan) | ||||
| Net cash flow from operating activities (yuan) | —— | —— | 2,105,916,826.72 | 10.73% |
| Basic earnings per share (yuan/share) | 0.3401 | -9.88% | 1.0832 | -20.74% |
| Diluted earnings per share (yuan/share) | 0.3401 | -9.88% | 1.0832 | -20.74% |
| Weighted average return on equity (ROE) | 3.75% | -1.00% | 12.28% | -5.41% |
| End of the current reporting period | End of last year | Change of the end of the current reporting period over the end of last year | ||
| Total assets (yuan) | 27,687,711,922.81 | 24,201,348,154.75 | 14.41% | |
| Owners’ equity attributable to shareholders of listed companies (yuan) | 16,250,585,502.88 | 14,619,821,308.60 | 11.15% | |
Share capital of the Company as of the trading day before disclosure:
| Share capital of the Company as of the trading day before disclosure (share) | 1,749,809,548 |
Fully diluted earnings per share calculated on the basis of the latest Share capital
| Dividends paid on preferred shares | 0.00 |
| Perpetual bond interest paid (yuan) | 0.00 |
| Fully diluted earnings per share calculated on the basis of the latest Share capital (yuan/share) | 1.0832 |
(II)Items and amounts of non-recurring gains/losses
√ Applicable □ N/A
| Item | Amount of the current reporting period | Amount (from the beginning of the year to the end of the reporting period) | Note |
| Gains/losses on disposal of non-current assets (including the written-off part of the accrued assets impairment reserve) | -356,832.47 | -466,951.55 | |
| Government grants included in current gains/losses(excluding those closely related to normal operating activities, in line with national policies and measured according to unified national standards) | 19,665,596.43 | 157,973,691.62 | |
| Receivables subject to separate impairment test and reversal of reserve for impairment | 5,388,185.00 | ||
| Other non-operating income or expenditure | 2,888,378.89 | -2,028,188.08 | |
| Less: Amount affected by income tax | -2,745,429.38 | 19,349,865.15 | |
| Amount affected by minority interest (after tax) | -2,056,495.07 | 8,152,366.87 | |
| Total | 26,999,067.30 | 133,364,504.97 | -- |
Details of other gains/losses items satisfying the definition of non-recurring gains/losses:
□ Applicable √ N/A
No such case.If the Company recognizes a non-recurring gain/loss listed in the “Interpretative Announcement No. 1 on Information DisclosureCriteria for Public Companies – Non-Recurring Profit/Loss” as a recurring gain/loss, reasons should be specified.
□ Applicable √ N/A
No such case.
(III)Changes in key accounting data and financial indicators and their reasons
√ Applicable □ N/A
| Unit: RMB yuan | ||||
| Balance sheet item | End of the period | Beginning of the period | Change rate | Notes on cause of changes |
| Accounts receivable financing | 572,080,968.64 | 828,659,217.25 | -30.96% | Mainly due to banker’s acceptance discount in the current period |
| Accounts receivable | 8,147,812,875.63 | 6,137,675,568.82 | 32.75% | Mainly due to income growth and capital return fluctuation |
| Other receivables | 299,688,469.54 | 87,269,489.82 | 243.41% | Mainly due to the increase of equity transfer accounts receivable and suspense accounts receivable |
| Other current assets | 38,039,156.52 | 85,654,691.58 | -55.59% | Mainly due to the decrease of input VAT to be deducted at the end of the period |
| Other equity instruments investment | 129,841,291.42 | 225,453,120.05 | -42.41% | Mainly due to the transfer of equity instrument investment of Ningbo Donghai Bank and the sale of some RAPT shares in the current period |
| Goodwill | 2,100,106,651.09 | 1,469,617,262.10 | 42.90% | Mainly due to the acquisition of Doer Biologics and High Tech in the current period |
| Notes payable | 1,381,336,643.84 | 554,336,058.71 | 149.19% | Mainly due to the increase of bill payment in the current period |
| Contract liabilities | 186,487,690.02 | 94,384,629.77 | 97.58% | Mainly due to the increase of advance drug payments in the current period |
| Non-current liabilities due within one year | 23,288,386.11 | 67,813,886.68 | -65.66% | Mainly due to the decrease of long-term payables and long-term borrowing due within one year |
| Long-term payables | 164,454,591.48 | 26,812,354.90 | 513.35% | Mainly due to the increase in contingent and deferred consideration resulting from the acquisition of external companies by the subsidiaries |
| Long term loan | 287,439,900.00 | 151,611,367.86 | 89.59% | Mainly due to the increase of subsidiaries’ long-term borrowing |
| Other comprehensive income | 91,912,418.43 | -2,191,069.45 | 4294.87% | Mainly due to the increase in the exchange differences from translation of foreign currency statements |
| Income statement item | Amount of the current period | Amount of the previous period | Change rate | Notes on cause of changes |
| Gains on assets disposal | -149,966.61 | 304,146,257.99 | -100.05% | Mainly due to the income from asset disposal of Sinclair in the previous period |
| Investment income | -60,001,493.40 | -20,950,134.64 | -186.40% | Mainly due to the increase of discount interest and the decrease of net profit of joint ventures in the current period |
| Cash flow statement item | Amount of the current period | Amount of the previous period | Change rate | Notes on cause of changes |
| Net cash flows from investing activities | -1,406,864,147.47 | -920,040,870.59 | -52.91% | Mainly due to the increase of equity investment in the current period |
II. Shareholder information(I) Total number of shareholders of common shares and number of shareholders of preferred shares with
voting rights restored, as well as information about top 10 shareholders
Unit: share
| Total number of shareholders of common shares at the end of the reporting period | 195,693 | Total number of shareholders of preferred shares whose voting rights have been restored at the end of the | 0 |
| reporting period (if any) | ||||||||
| Information about top 10 shareholders | ||||||||
| Name | Nature | Shareholding ratio | Number of shares held | Number of shares held with sale restrictions | Pledged, marked or frozen | |||
| Status | Number | |||||||
| China Grand Enterprises, Inc. | Domestic non-state-owned legal person | 41.77% | 730,938,157 | 0 | Pledged | 238,450,000 | ||
| Hangzhou Huadong Medicine Group Co., Ltd. | State-owned legal person | 16.46% | 288,000,000 | 0 | ||||
| Hong Kong Securities Clearing Company Ltd. | Overseas legal person | 1.75% | 30,641,915 | 0 | ||||
| China Securities Finance Co., Ltd. | Domestic non-state-owned legal person | 1.27% | 22,186,818 | 0 | ||||
| National Social Security Fund Portfolio 503 | Others | 0.49% | 8,500,086 | 0 | ||||
| #Liu Li | Domestic natural persons | 0.34% | 6,000,000 | 0 | ||||
| Basic Endowment Insurance Fund Portfolio 15041 | Others | 0.27% | 4,682,950 | 0 | ||||
| #Chen Shaoming | Domestic natural persons | 0.21% | 3,744,388 | 0 | ||||
| Norges Bank－own funds | Overseas legal person | 0.16% | 2,776,229 | 0 | ||||
| China Merchants Bank Co., Ltd.－Xingquanheyuan 2-year Holding Mixed Securities Investment Fund | Others | 0.15% | 2,609,639 | 0 | ||||
| Shares held by the top 10 shareholders of Non- restricted shares | ||||||||
| Name | Number of shares held without sale restrictions | Type of shares | ||||||
| Type | Number | |||||||
| China Grand Enterprises, Inc. | 730,938,157 | RMB common shares | 730,938,157 | |||||
| Hangzhou Huadong Medicine Group Co., Ltd. | 288,000,000 | RMB common shares | 288,000,000 | |||||
| Hong Kong Securities Clearing Company Ltd. | 30,641,915 | RMB common shares | 30,641,915 | |||||
| China Securities Finance Co., Ltd. | 22,186,818 | RMB common shares | 22,186,818 | |||||
| National Social Security Fund Portfolio 503 | 8,500,086 | RMB common shares | 8,500,086 | |||||
| #Liu Li | 6,000,000 | RMB common shares | 6,000,000 | |||||
| Basic Endowment Insurance Fund Portfolio 15041 | 4,682,950 | RMB common shares | 4,682,950 | |||||
| #Chen Shaoming | 3,744,388 | RMB common shares | 3,744,388 | |||||
| Norges Bank－own funds | 2,776,229 | RMB common shares | 2,776,229 |
| China Merchants Bank Co., Ltd.－Xingquanheyuan 2-year Holding Mixed Securities Investment Fund | 2,609,639 | RMB common shares | 2,609,639 |
| Notes on relations and concerted actions among the shareholders mentioned above | The Company does not know whether the shareholders mentioned above are related parties with each other or whether they are acting-in-concert parties with each other. | ||
| Notes on financing and securities loan conducted by top 10 shareholders (if any) | At the end of the current reporting period, Liu Li, the sixth shareholder of the Company, held 6,000,000 shares of the Company through financing and securities loan, Chen Shaoming, the eighth shareholder of the Company, held 3,651,388 shares of the Company through financing and securities loan. | ||
(II)Total number of shareholders of preferred shares and information about top 10 shareholders ofpreferred shares
□ Applicable √ N/A
III. Other important matters
√ Applicable □ N/A
(I) Overview of operations
1. The Company’s operations during the reporting period
In the first three quarters of 2021, the Company deepened the transformation and innovationwork. The performance of business indicators in the reporting period decreased year-on-year, buthas been significantly improved compared with the first half of the year, and the overall operationmaintained a stable and positive trend. The core subsidiary Zhongmei Huadong actively overcamethe business and market pressure brought about by the reform of the domestic pharmaceuticalindustry, accelerated the process of innovation and internationalization, and strengthened thedevelopment of out-of-hospital and grass-roots markets. In the first three quarters of 2021, theoperating income reached RMB7.804 billion, down 11.4% year on year, and the net profit wasRMB1.72 billion, down 11.1% year on year. While the sales volume of main products wasincreasing, the income from immunity and cardiovascular products continued to increase rapidly.The export of customized high-end bulk drugs (Contract Development and ManufacturingOrganization, CDMO) and e-commerce business continued to develop, reflecting the resilience andgrowth potential of the Company’s pharmaceutical manufacturing business as a whole. In the thirdquarter, Zhongmei Huadong was affected by product price reduction continuously, with theoperating income decreasing by 12.7% year on year but increasing by 2.0% quarter on quarter, andthe net profit decreasing by 5.2% year on year (compared with 14.6% year-on-year decline of thefirst quarter of 2021 and 11.7% year-on-year decline of the second quarter of 2021, indicating the
trend of narrowing decline and stabilization) but increasing by 14.8% quarter on quarter, which haslaid a solid foundation for returning to growth in 2022. In the fourth quarter, the Company willmake every effort to manage the operation, strive to achieve growth in the quarter, and endeavor toachieve the operating objectives of the whole year.Ellansé
?, the core aesthetic medicine product of the Company, has been officially placed onthe Chinese mainland market at the end of August. It has been accurately positioned for high-endregeneration market with its unique advantages of “immediate filling, lasting effect and beingmetabolizable”. Currently, the number of contracted cooperative hospitals for the product exceeds120, the number of trained and certified doctors exceeds 200, and its sales and promotion was ready.Ellansé
?
has received extensive attention and popularity from the market since its launch, with astack of orders from aesthetic medicine institutions and good feedback from customers. As of therelease date of this report, the Company has received advances of more than RMB100 million forthe product, and is expected to beat the annual sales target, and drive the Company’s domesticaesthetic medicine business to achieve new growth in 2022 based on the head start this year. Facingthe strong demand in the domestic market, the Company requires Sinclair’s Dutch factory to givepriority to the supply in the domestic market, thus shortening the waiting time of customers. At thesame time, the Company will strictly select cooperative institutions and constantly increase thetraining and certification of doctors to provide responsible and high-quality services to customers.Moreover, to meet the demand growth of Ellansé
?in the global market, in addition to the factory inUtrecht in the Netherlands, Sinclair built a new factory in Almere, Netherlands, to expand itscapacity. At present, the new factory is completed and put into use after passing the certification andapproval, so as to fully ensure the subsequent supply of Ellansé
?around the globe.During the reporting period, the Company’s overseas aesthetic medicine business continued toshow rapid growth with the relaxation of pandemic containment measures in various countries. Thesales of Ellansé
?, the core product of Sinclair UK, MaiLi
?series product, a newly-launchedhigh-end hyaluronic acid filler in Europe, Lanluma
?
, a collagen stimulant, and other productscontinued to outperform the expectation. In the first three quarters of 2021, Sinclair’s operatingincome (including acquired Spanish company High Tech) was GBP53.06 million (approximatelyRMB473 million) with a year-on-year increase of 127.4%. Specifically, Sinclair’s own incomeincreased by 79.24%, and its annual income is expected to reach the highest level in history. Drivenby good sales in the end market, High Tech received sufficient orders during the year, which hasprovided a strong guarantee for the rapid growth of annual income. In the first three quarters of2021, affected by factors such as non-recurring expenses for the acquisition of High Tech’s equities,Sinclair’s net profit in the overall consolidated statement still showed a loss, but its earnings before
interest, taxes, depreciation and amortization (i.e. EBITDA) was GBP5.06 million (consolidatedspecifications), the highest EBITDA since the Company completed the buyout of Sinclair in 2018,and also important evidence of the Company’s ability to run the aesthetic medicine business aroundthe globe.
Huadong Pharmaceutical Distribution Company has actively optimized the in-hospital marketand expanded the out-of-hospital market, and the overall business maintained a stable growth. In thefirst three quarters of 2021, the Company’s pharmaceutical commerce segment achieved anoperating income of RMB17.268 billion with a year-on-year increase of 7.03%. The establishmentof product promotion teams has been accelerated, and the number of innovative drugs introduced tosell by proxy during the year has exceeded that in 2020. The third-party logistics business ofpharmaceutical commerce continued with rapid growth, with the phased task of the distribution ofCOVID-19 vaccines in Zhejiang Province being fully completed. The construction of Jinhualogistics center entered the final stage. During the reporting period, the Company was also selectedas a key e-commerce platform enterprise in 2021-2022 in Zhejiang Province.The main reason for the difference between year-on-year decrease in the Company’s net profitand the net profit after deducting non-recurring profits and losses in the reporting period is that theCompany’s non-recurring profits and losses in the first quarter of 2020 were RMB290 million,including a net income of GBP30.65 million from the transfer of regional product distribution rightsby Sinclair to Galderma, which greatly increased the Company’s overall income in the first quarterof 2020. No such matters occurred during the reporting period, and other non-recurring gains andlosses totaled RMB133 million in the first three quarters of 2021, resulting in a decrease in the netprofit attributable to shareholders of the listed company year on year.
2. Building an R&D ecosystem of the Company and accelerating the process ofinnovation and internationalization
During the reporting period, Zhongmei Huadong and Huadong Medicine Investment Holding(Hong Kong) Co., Ltd. (hereinafter referred to as the “Investment Holding”), wholly-ownedsubsidiaries of the Company, signed an equity investment agreement and exclusive product licenseagreement with Ashvattha Therapeutic, Inc. (hereinafter referred to as “Ashvattha”). InvestmentHolding will subscribe for Series B preferred shares issued by Ashvattha in stages. Meanwhile,Zhongmei Huadong will obtain the exclusive license of Ashvattha’s 8 products under research in 20Asian countries and regions such as China, Singapore and Malaysia, including the use ofAshvattha’s relevant intellectual property rights for R&D, production and commercialization.
Ashvattha is an innovative biopharmaceutical enterprise focusing on the development ofhydroxyl dendrimer (HD) therapeutics (HDTs). Based on interdisciplinary transformation research
of dendrimers that can cross the tissue barrier, its scientific research team connects activepharmaceutical ingredients (API) or imaging agent with HD to form new patented drugs, which canachieve precise treatment by targeting disease cells and have clinical significance and applicationprospect. Ashvattha applies the technology of nanomedicine and nano materials. Its unique HDplatform is the only hydroxyl dendrimer platform capable of producing highly selective drugs in theworld. Ashvattha has a reasonable patent portfolio and has the potential to develop a variety oftherapeutic drugs.
Ashvattha was founded by three scientists, namely, Dr. Kannan Rangaramanujam, the ArnallPatz distinguished professor of ophthalmology and co-director of center for nanomedicine at theWilmer Eye Institute at Johns Hopkins School of Medicine, Dr. Sujatha Kannan, the Richard J.Traystman Professor and Vice chair of research in Anesthesiology and Critical Care Medicine(ACCM) at Johns Hopkins School of Medicine, and Dr. Jeffrey Cleland, who graduated fromMassachusetts Institute of Technology in chemical engineering, worked for Genentech andcommitted to new drug research and development for more than ten years. The three founders havemade achievements in the field of medicine, published a large number of academic articles andowned dozens of invention patents. In addition, Ashvattha also has a team of professionalconsultants with rich research experience and professional experience.The Company introduced eight products under research from Ashvattha, covering the fields oftumor, metabolic comorbidity, inflammation, etc.. One of the products has entered phase II clinicaltrial in the United States, and two products will be submitted for IND review in the United States inthe first quarter of 2022. This cooperation will further enrich the Company’s innovative productpipeline in the fields of tumor, immunity and endocrinology, and help to improve the Company’sinternationalization and scientific research innovation level. In the future, the products will alsoprovide doctors and patients with more precise and scientific diagnosis and treatment andmedication options after launching.The Company has invested, held shares in and incubated a number of domestic biotechnologycompanies with leading technology. For example, it invested in Peg-Bio Biopharm featuring apeptide technology platform, Qyuns Therapeutics, an antibody company focusing on immunediseases, and Nuoling Biomedical Technology featuring ADC linker and coupling technology; itincubated Huida Biotech which has a full line of toxin ingredients used to develop ADC drugs; andit holds stakes in Doer Biologics which focuses on the development of a Polyclonal antibodyplatform. Through those efforts, the Company has gradually formed its own medical R&Decosystem. The cooperation with Ashvattha and the introduction of its HD platform technology willbecome an important part of the Company’s efforts to build an R&D ecosystem and accelerate its
process of innovation and internationalization.
3. Continuing to enrich product lines and enhancing the competitiveness of diabetesmedicineDuring the reporting period, the application for marketing authorization regarding theindications for diabetes of the Company’s GLP-1 receptor agonist Liraglutide injection wasaccepted in September 2021. In addition to the original research company, there is no domesticmanufacturer applying for its marketing authorization. Therefore, the Company is expected tobecome the first enterprise in China to obtain approval for the marketing authorization ofLiraglutide’s biosimilar. Furthermore, the Company has carried out phase III clinical research on theindication for weight loss of Liraglutide injection. At present, the enrollment has been completedand a follow-up visit is underway. It is planned to carry out the application for marketingauthorization by the end of 2021.
In September 2021, the Company granted the exclusive development, production andcommercialization rights of the world’s first small-molecule oral GLP-1 receptor agonist TTP273 inKorea to Daewon Pharmaceutical Co., Ltd. of South Korea, which is the Company’s firstlicense-out of innovative products (see the relevant announcement issued by the Company onSeptember 30, 2021).
In October, the Company entered into strategic cooperation with Takeda PharmaceuticalsCompany Ltd. (hereinafter referred to as “Takeda”) on the commercialization rights of globallyinnovative DPP-4 inhibitor Nesina
?(Alogliptin Benzoate Tablets) in China, which has been
launched in China, further enriching the Company’s diabetes product portfolio, forming synergywith the Company’s existing key products in the field of diabetes, and continuously consolidatingand enhancing the competitiveness and leading position of the Company in the field of diabetesmedicine in China. The alliance with Takeda also shows the industry’s affirmation of thecommercialization ability of the Company in the local market of diabetes medicine.
The company has been engaged in the field of diabetes medicine for nearly 20 years, hasestablished a product matrix of core therapeutic targets and mainstream clinical drugs, and alreadyhas more than 20 commercialized products and products under research. The diabetes medicinemarket will continue to be a core area for the Company to expand its layout in the future. TheCompany will actively accelerate the process of innovation and industrialization throughindependent research and development, cooperation, equity investment and other diversified modes,continuously provide cutting-edge and advanced drugs in the world, continuously broaden the roadof internationalization and make progress towards the world’s leading diabetes medicinemanufacturing enterprise.
4. Building a non-invasive + minimally invasive high-end product pipeline to bring a newgrowth momentum to the global aesthetic medicine business
During the reporting period, Sinclair cooperated with KiOmed in Belgium to obtain theexclusive license of four globally innovative KiOmedine
?
chitosan products under research and allsubsequent chitosan related aesthetic medicine products in the field of aesthetic medicine for skin inother regions of the world except the United States, including the use of KiOmed related intellectualproperty rights for R&D, production and commercialization. The cooperation is another importantstrategic measure for global layout of the Company in the field of light aesthetic medicine, will
further enrich the Company’s innovative filler product pipeline of aesthetic medicine, and realizethe full coverage of products in the fields of hyaluronic acid, collagen stimulant, skin booster and soon. KiOmedine
?is a high-purity natural (non-animal-sourced) medical chitosan derivativedeveloped by KiOmed using its unique patented technology. Compared with hyaluronic acid,KiOmedine
?is characterized by deep moisturizing, increasing collagen level and anti-aging. Inaddition, KiOmedine
?series fillers are expected to further prolong the action time of hyaluronicacid and achieve long-acting filling effect. At present, there is no similar product in the market allover the world. The future launch of the product is expected to change the product landscape of thehyaluronic acid market and will become another potential blockbuster product in the field besideshigh-end hyaluronic acid MaiLi
?
.The Company introduced a cold-touch cosmetic instrument from R2 Company,
Glacial Spa
TM
(F0, life cosmetology version of a frozen freckle-removing medical device), has obtained marketingapproval in Korea and Taiwan of China, and the Non-medical Devices Management Certificationfrom NMPA. It is expected to be officially marketed in China in the fourth quarter of 2021.Cooperation intentions have been reached with some beauty institutions.In addition, the Company has made launching plans in China for the main products on saleoverseas and innovative products under research of the wholly-owned subsidiary High Tech inSpain engaged in energy source aesthetic medicine devices, and the relevant registrationpreparations have been carried out orderly. In particular, the registration of cryolipolysis productCooltech Define and laser hair removal device Primelase in China will be officially launched beforethe end of 2021. Safyre, an RF product marketed overseas and suitable for facial rejuvenation andbody shaping, is expected to be rolled out in China in the second quarter of 2022.
The Company will continue to accelerate the progress of clinical registration and promotion ofcore aesthetic medicine products at home and abroad, and continuously improve the competitiveadvantage in the industry by penetrating the global high-end aesthetic medicine market. After threeyears of rapid development, the Company’s aesthetic medicine business has achieved phasedstrategic objectives, and developed more than 20 products in the field of non-invasive + minimallyinvasive aesthetic medicine, with the number and coverage among the front rank of the industry. Ofthose products, several are expected to be released and sold at home and abroad before 2025,bringing new growth momentum to the Company’s global aesthetic medicine business.
Note 1: Due to the liquidation of Huadong Ningbo after its operations expire, there is still uncertainty about the subsequent ownership of the interests in the commercialization ofbotulinum toxin products in China with Jetema of South Korea.
| 肉毒素埋线 | ||||||||
| Ellansé?伊妍仕?注射用聚己内酯微球 | Lanluma?（聚左旋乳酸类胶原蛋白刺激剂） | MaiLi?系列新型高端含利多卡因透明质酸 | Perfectha?系列双相透明质酸 | 与Kylane公司合作两款重点研发产品 | 皮肤动能素（天然<非动物源>羧烷基壳聚糖注射剂） | 3款KiOmedine?填充剂（天然<非动物源>羧烷基壳聚糖和透明质酸注射剂） | Botulinum Toxin 1（A型肉毒素） | 美容埋线Silhouette?Instalift? |
| 除皱 | 适用于中面部提拉手术短暂固定并提拉脸颊下真皮位置 | |||||||
| 中国注册上市推进中 | 美国 FDA 认证全球 60 多个国家获地区获注册认证或上市准入预计 2024 年在中国上市 | ||||||||
填充皮肤美白提亮
| 脱毛脱毛脱毛 |
| 海外已上市 | 海外研发阶段预计 2023 年获得欧盟 CE认证 | 海外研发阶段预计 2024 年获得欧盟 CE认证 | 海外研发阶段预计 2022年获得欧盟 CE认证 | 预计2022年中国上市 | 全球 11 个国家或地区获 注册认证或上市准入 | 海外研发阶段预计 2023 年获得欧盟 CE认证 | 全球 7 个国家或地区获注册认证或上市准入 | ||||||||||||
| 皮肤管理 | 身体塑形 | 脱毛 | ||||||||||
| 酷雪?Glacial Spa?（F0） | F1（Glacial Rx?） | F2（Glacial Ai） | Cooltech | Cooltech Define | Crystile | Define2.0 | Define3.0 | Titania | Safyre | Primelase | Primelase Pro | Elysion |
(II) Research and development and registrationDuring the reporting period, the Company continued to accelerate the R&D work, with a totalR&D investment of RMB904 million in the pharmaceutical industry, a year-on-year increase of
8.9%. The clinical study and registration of products under research in the Company’s core areas isadvancing in an orderly manner.As of the release of the report, the main R&D and registration progress of the Company’smedicine business is as follows:
1. Diabetes
The application for marketing authorization regarding the indication for diabetes of GLP-1receptor agonist Liraglutide injection was accepted in September 2021. The non-clinical study ofInsulin Aspart injection was completed, and it is expected that the application for IND review willbe submitted in the first quarter of 2022. HDM1003 (SCO-094) is a dual agonist that targets bothGLP-1R and GIPR for the treatment of diseases such as type 2 diabetes, obesity and non-alcoholicsteatohepatitis (NASH), jointly developed by the Company and SCOHIA PHARMA, Inc. in Japan.Its Phase I clinical trial is being carried out in the United Kingdom, and the Pre-IND application inChina has been submitted. DR10624 is a multiple agonist under research by the holding subsidiaryZhejiang Doer Biologics Corporation that targets GLP-1R/GCGR/FGF21, which can be used forthe treatment of diseases such as type 2 diabetes, obesity and NASH. The preparations of its phase Iclinical trial overseas and pre-IND application in China in 2022 are underway.
2. Tumor
HDM2002 (IMGN853), developed jointly by the Company and ImmunoGen of the UnitedStates, is the world’s first ADC drug for FR α-positive ovarian cancer. Its phase III multi-regionalclinical trial has been initiated in China, and it is expected that clinical enrollment will be completedin 2022. The clinical enrollment of another key single-arm clinical trial of the drug has beencompleted in the United States and Europe in the second quarter, and preliminary test results areexpected to be obtained by the end of 2021. Mefatinib for the treatment of advanced non-small celllung cancer is under phase III clinical trial, and the enrollment of the subjects for the phase IIIclinical trial has been completed. It is expected to carry out application for marketing authorizationafter the completion of phase III clinical trial in 2022. DR30303 is a product under research of theholding subsidiary Zhejiang Doer Biologics Corporation for the treatment of gastric cancer andpancreatic cancer, and feedback has been received from CDE concerning its application forpre-IND. Its phase I clinical trial will be launched in China in 2022 after IND approval.
3. Autoimmunity
The Company introduced HDM3002 (PRV-3279), a bispecific antibody under research of
Provention Bio (USA) for the treatment of systemic lupus erythematosus (SLE) and for preventingor reducing the immunogenicity of gene therapy. At present, pre-IND materials have been submittedin China and feedback has been received. The phase II multi-regional clinical trial of this productwill be initiated in China. HDM3001 (QX001S) is a biosimilar of the original drug ustekinumab(Stelara?) jointly developed by the Company and its partially-owned company Qyuns Therapeuticsand used to treat moderate-to-severe psoriasis of adults. Its phase III clinical trial is underway.
4. Rare diseases
Sirolimus Oral Solution produced by the Company has been used clinically to treat a rarepediatric disease tuberous sclerosis complex (TSC) for many years. In view of the urgent clinicalneeds of children with TSC for approved effective treatment, the Company has submitted a pre-INDapplication to CDE and plans to carry out a real-world study to support the expansion of theindications.
5. Medicine/medical device
HD-NP-102 (MB102, dynamic TGFR monitoring system): A product jointly developed by theCompany and Medibeacon, Inc. of the United States for the evaluation of the renal function ofhealthy people and patients through real-time percutaneous monitoring of glomerular filtration rate.With its accurate diagnosis and risk assessment of early renal injury, the product is ofground-breaking clinical significance. The Company has submitted an application for innovativemedical devices to the Center for Medical Device Evaluation of National Medical ProductsAdministration, and the phase III multi-regional clinical trial will be launched by the end of 2021.
(III) Other important matters
In August 2021, the natural person shareholders of the Company’s holding subsidiary HuadongNingbo Medicine Co., Ltd. (hereinafter referred to as “Huadong Ningbo”) filed a lawsuit to thePeople’s Court of Beilun District of Ningbo for an order to dissolve Huadong Ningbo in advance onthe grounds that there were serious difficulties in the operation and management of HuadongNingbo and that the continuing operation of Huadong Ningbo would cause material losses toshareholders. The Company claimed that Huadong Ningbo should enter the legal liquidation afterits operation expires on December 31, 2021, but did not agree to dissolve Huadong Ningbo inadvance. The case was heard in People’s Court of Beilun District of Ningbo on September 22, 2021,and has not been sentenced yet. Afterward, the Company held meetings with natural personshareholders and management representatives of Huadong Ningbo on relevant matters. The twoparties have reached a consensus that Huadong Ningbo has entered the liquidation preparationperiod, will mainly carry out capital withdrawal before the end of 2021, and will not conduct newbusiness. The parties agree to speed up the preparations for the liquidation of Huadong Ningbo. To
be responsible to all shareholders and safeguard the interests of all shareholders, the Company willproperly carry out the subsequent liquidation of Huadong Ningbo according to law.IV. Quarterly financial statements
(I) Financial Statements
1. Consolidated balance sheet
Prepared by Huadong Medicine Co., Ltd.
Unit: RMB yuan
| Item | September 31, 2021 | December 31, 2020 |
| Current assets: | ||
| Monetary funds | 3,366,668,781.24 | 3,198,080,997.82 |
| Settlement reserve | ||
| Lending to other banks and other financial institutions | ||
| Financial assets for trade | ||
| Derivative financial assets | ||
| Notes receivable | ||
| Accounts receivable | 8,147,812,875.63 | 6,137,675,568.82 |
| Accounts receivable financing | 572,080,968.64 | 828,659,217.25 |
| Advance payments | 291,583,511.06 | 250,916,482.07 |
| Premiums receivable | ||
| Reinsurance accounts receivable | ||
| Reinsurance contract reserve receivable | ||
| Other receivables | 299,688,469.54 | 87,269,489.82 |
| Including: Interests receivable | 15,972,701.53 | |
| Dividends receivable | 832,286.37 | 4,195,666.37 |
| Financial assets purchased for resale | ||
| Inventories | 4,129,417,606.73 | 4,067,635,254.80 |
| Contract assets | ||
| Assets held for sale | ||
| Non-current assets due within one |
| year | ||
| Other current assets | 38,039,156.52 | 85,654,691.58 |
| Total current assets | 16,845,291,369.36 | 14,655,891,702.16 |
| Non-current assets: | ||
| Loans and prepayments issuance | ||
| Debt investments | ||
| Other debt investments | ||
| Long-term receivables | ||
| Long-term equity investments | 950,889,474.55 | 850,072,053.02 |
| Other equity instrument investments | 129,841,291.42 | 225,453,120.05 |
| Other non-current financial assets | ||
| Real estate properties for investment | 17,082,267.95 | 17,792,735.95 |
| Fixed assets | 3,106,575,021.33 | 2,420,366,582.92 |
| Constructions in progress | 1,864,058,365.39 | 2,240,201,926.65 |
| Biological assets for production | ||
| Oil & gas assets | ||
| Right-of-use assets | 161,568,723.35 | |
| Intangible assets | 1,707,792,705.74 | 1,463,242,463.99 |
| Development expenditures | ||
| Goodwill | 2,100,106,651.09 | 1,469,617,262.10 |
| Long-term unamortized expenses | 10,511,051.56 | 8,811,339.43 |
| Deferred income tax assets | 151,508,607.37 | 137,829,774.40 |
| Other non-current assets | 642,486,393.70 | 712,069,194.08 |
| Total non-current assets | 10,842,420,553.45 | 9,545,456,452.59 |
| Total assets | 27,687,711,922.81 | 24,201,348,154.75 |
| Current liabilities: | ||
| Short-term borrowing | 1,280,558,172.04 | 1,416,932,884.87 |
| Borrowing from the Central bank | ||
| Borrowing from other banks and other financial institutions | ||
| Financial liabilities for trade | ||
| Derivative financial liabilities | ||
| Notes payable | 1,381,336,643.84 | 554,336,058.71 |
| Accounts payable | 4,292,982,588.65 | 3,947,044,331.68 |
| Advance receipts | 1,906,357.52 | 951,926.56 |
| Contract liabilities | 186,487,690.02 | 94,384,629.77 |
| Financial assets sold for repurchase | ||
| Absorbing deposits and due from banks | ||
| Receipts for buying and selling securities as proxy | ||
| Receipts for underwriting securities as proxy | ||
| Employee benefits payable | 160,461,686.62 | 152,106,819.91 |
| Taxes and fees payable | 565,343,178.21 | 571,792,475.80 |
| Other payables | 2,084,232,842.01 | 1,817,529,820.99 |
| Including: Interests payable | ||
| Dividends payable | 224,219.60 | 224,219.60 |
| Handling fees and commissions payable | ||
| Reinsurance accounts payable | ||
| Liabilities held for sale | ||
| Non-current liabilities due within one year | 23,288,386.11 | 67,813,886.68 |
| Other current liabilities | 30,059,800.64 | 10,786,034.37 |
| Total current liabilities | 10,006,657,345.66 | 8,633,678,869.34 |
| Non-current liabilities: | ||
| Insurance contract reserve | ||
| Long-term borrowing | 287,439,900.00 | 151,611,367.86 |
| Bonds payable | ||
| Including: Preferred shares | ||
| Perpetual bonds | ||
| Lease liabilities | 148,719,237.87 | |
| Long-term payables | 164,454,591.48 | 26,812,354.90 |
| Long-term employee benefits payable | ||
| Provision | 37,410,969.95 | 39,467,829.23 |
| Deferred gains | 83,907,277.33 | 81,628,032.54 |
| Deferred income tax liabilities | 83,108,397.29 | 88,738,187.41 |
| Other non-current liabilities | ||
| Total non-current liabilities | 805,040,373.92 | 388,257,771.94 |
| Total liabilities | 10,811,697,719.58 | 9,021,936,641.28 |
| Ownership interest: | ||
| Share capital | 1,749,809,548.00 | 1,749,809,548.00 |
| Other equity instruments | ||
| Including: Preferred shares | ||
| Perpetual bonds | ||
| Capital reserve | 2,158,080,661.07 | 2,158,080,661.07 |
| Less: Treasury shares | ||
| Other comprehensive income | 91,912,418.43 | -2,191,069.45 |
| Special reserve | ||
| Surplus reserve | 863,793,516.20 | 861,680,578.42 |
| General risk reserve | ||
| Undistributed profit | 11,386,989,359.18 | 9,852,441,590.56 |
| Total ownership interest attributable to the parent company | 16,250,585,502.88 | 14,619,821,308.60 |
| Minority interest | 625,428,700.35 | 559,590,204.87 |
| Total ownership interest | 16,876,014,203.23 | 15,179,411,513.47 |
| Total liabilities & ownership interest | 27,687,711,922.81 | 24,201,348,154.75 |
Legal representative: Lv LiangOfficer in charge of accounting: Lv LiangHead of accounting department : Qiu Renbo
2. Consolidated income statement from the beginning of the year to the end of the reporting period
Unit: RMB yuan
| Item | Amount incurred during the current period | Amount incurred during the previous period |
| I. Total operating income | 25,927,477,363.27 | 25,500,876,607.95 |
| Including: Operating income | 25,927,477,363.27 | 25,500,876,607.95 |
| Interests received | ||
| Premiums earned | ||
| Handling fees and commissions received |
| II. Total operating cost | 23,721,020,429.04 | 22,945,770,445.69 |
| Including: Operating cost | 17,820,264,592.12 | 16,739,900,305.18 |
| Interests paid | ||
| Handling fees and commissions paid | ||
| Surrender value | ||
| Net payment of insurance claims | ||
| Net appropriation of policy reserve | ||
| Policy dividends paid | ||
| Reinsurance expenses | ||
| Taxes and surcharges | 132,071,642.16 | 148,487,687.03 |
| Selling expenses | 4,165,255,628.17 | 4,575,928,264.87 |
| Administrative expenses | 859,932,896.49 | 775,033,097.55 |
| R&D expenses | 727,596,640.52 | 689,897,925.27 |
| Financial expenses | 15,899,029.58 | 16,523,165.79 |
| Including: Interests paid | 59,960,711.55 | 59,381,737.63 |
| Interests received | 64,850,873.74 | 52,891,384.64 |
| Add: Other gains | 157,965,604.53 | 123,759,645.82 |
| Investment gains (Losses are indicated by “-”) | -60,001,493.40 | -20,950,134.64 |
| Including: Investment gains from associates and joint ventures | -18,970,341.98 | -9,025,650.76 |
| Gains from the derecognition of financial assets measured at amortized cost | ||
| Gains on exchange (Losses are indicated by “-”) | ||
| Gains on net exposure hedging (Losses are indicated by “-”) | ||
| Gains on changes in fair value (Losses are indicated by “-”) | ||
| Credit impairment loss (Losses are indicated by “-”) | -38,263,673.24 | -29,841,283.63 |
| Assets impairment loss (Losses are indicated by “-”) | 3,054,806.20 |
| Gains on assets disposal (Losses are indicated by “-”) | -149,966.61 | 304,146,257.99 |
| III. Operating profit (Losses are indicated by “-”) | 2,269,062,211.71 | 2,932,220,647.80 |
| Add: Non-operating income | 17,439,095.86 | 16,504,085.99 |
| Less: Non-operating expenditure | 19,888,568.89 | 26,367,259.87 |
| IV. Total profit (Total losses are indicated by “-”) | 2,266,612,738.68 | 2,922,357,473.92 |
| Less: Income tax expenses | 324,435,752.43 | 462,041,510.71 |
| V. Net profit (Net losses are indicated by “-”) | 1,942,176,986.25 | 2,460,315,963.21 |
| (I) Categorized by the continuity of operations | ||
| 1. Net profit from continued operations (Net deficit is indicated by “-”) | 1,942,176,986.25 | 2,460,315,963.21 |
| 2. Net profit from discontinued operations (Net deficit is indicated by “-”) | ||
| (II) Categorized by attribution of the ownership | ||
| 1. Net profit attributable to owners of the parent company | 1,895,384,579.34 | 2,391,466,604.78 |
| 2. Gains/losses of minority shareholders | 46,792,406.91 | 68,849,358.43 |
| VI. Net amount after tax of other comprehensive income | 115,596,732.48 | 21,024,507.92 |
| Net amount after tax of other comprehensive income attributable to owners of the parent company | 115,596,732.48 | 21,024,507.92 |
| (I) Other comprehensive income that cannot be reclassified into gains/losses | 18,270,393.86 | 5,817,290.26 |
| 1. Changes in remeasurement on the defined benefit plan | ||
| 2. Other comprehensive income that cannot be reclassified into gains/losses under equity method | ||
| 3. Changes in fair value of | 18,270,393.86 | 5,817,290.26 |
| other equity instrument investments | ||
| 4. Changes in fair value of credit risk of the enterprise | ||
| 5. Others | ||
| (II) Other comprehensive income to be reclassified into gains/losses | 97,326,338.62 | 15,207,217.66 |
| 1. Other comprehensive income that can be reclassified into gains/losses under equity method | ||
| 2. Changes in fair value of other debt investments | ||
| 3. Amount of financial assets reclassified into other comprehensive income | ||
| 4. Credit impairment reserve of other debt investments | ||
| 5. Cash flow hedging reserve | ||
| 6. Exchange differences arise from translation of foreign currency financial statements | 97,326,338.62 | 15,207,217.66 |
| 7. Others | ||
| Net amount after tax of other comprehensive income attributable to minority shareholders | ||
| VII. Total comprehensive income | 2,057,773,718.73 | 2,481,340,471.13 |
| Total comprehensive income attributable to owners of the parent company | 2,010,981,311.82 | 2,412,491,112.70 |
| Total comprehensive income attributable to minority shareholders | 46,792,406.91 | 68,849,358.43 |
| VIII. Earnings per share (EPS): | ||
| (I) Basic EPS | 1.0832 | 1.3667 |
| (II) Diluted EPS | 1.0832 | 1.3667 |
As for enterprise merger under the same control in the current period, the net profit generated by the merged party before the mergeris 0 yuan, and that generated during the previous period is 0 yuan.
Legal representative: Lv LiangOfficer in charge of accounting: Lv LiangHead of accounting department : Qiu Renbo
3. Consolidated cash flow statement from the beginning of the year to the end of the reporting period
Unit: RMB yuan
| Item | Amount incurred during the current period | Amount incurred during the previous period |
| I. Cash flows from operating activities: | ||
| Cash from the sale of goods and provision of services | 27,674,577,148.04 | 26,358,487,943.05 |
| Net increase in customer deposits and due from banks | ||
| Net increase in borrowing from the central bank | ||
| Net increase in borrowing from other financial institutions | ||
| Cash from the premium of the original insurance policy | ||
| Net cash from reinsurance | ||
| Net increase in deposits and investment of the insured | ||
| Cash from interests, handling fees and commissions | ||
| Net increase in borrowing from other banks and other financial institutions | ||
| Net increase in funds for repurchase | ||
| Net cash received for buying and selling securities as proxy | ||
| Tax refund received | 11,649,988.97 | 17,066,804.84 |
| Other cash receipts in relation to operating activities | 529,610,507.12 | 862,918,296.18 |
| Total cash inflows from operating activities | 28,215,837,644.13 | 27,238,473,044.07 |
| Cash payments for goods and services | 18,596,693,102.88 | 17,276,216,270.79 |
| Net increase in customer loans and prepayments | ||
| Net increase in deposits of central bank and due from banks |
| Cash for payment of original insurance claims | ||
| Net increase in lending to other banks and other financial institutions | ||
| Cash for payment of interests, handling fees and commissions | ||
| Cash for payment of policy dividends | ||
| Cash payments to and for employees | 1,822,563,793.72 | 1,623,091,615.04 |
| Payment of taxes and fees | 1,531,826,498.86 | 1,795,768,635.77 |
| Other cash payments in relation to operating activities | 4,158,837,421.95 | 4,641,582,165.81 |
| Total cash outflows for operating activities | 26,109,920,817.41 | 25,336,658,687.41 |
| Net cash flows from operating activities | 2,105,916,826.72 | 1,901,814,356.66 |
| II. Cash flows from investing activities | ||
| Cash from recovery of investments | 20,432,161.82 | |
| Cash from investment gains | 4,281,616.50 | 900,000.00 |
| Net cash from disposal of fixed assets, intangible assets and other long-term assets | 2,009,441.20 | 349,442,817.74 |
| Net cash from disposal of subsidiaries and other business units | ||
| Other cash receipts in relation to investing activities | 29,602,856.85 | |
| Total cash inflows from investing activities | 56,326,076.37 | 350,342,817.74 |
| Cash payments for purchase and construction of fixed assets, intangible assets and other long-term assets | 539,567,188.77 | 864,848,688.33 |
| Cash payments for investment | 120,706,000.00 | 70,535,000.00 |
| Net increase in pledge loans | ||
| Net cash paid for acquisition of subsidiaries and other business units | 776,789,194.67 | 335,000,000.00 |
| Other cash payments in relation to investing activities | 26,127,840.40 | |
| Total cash outflows for investing | 1,463,190,223.84 | 1,270,383,688.33 |
| activities | ||
| Net cash flows from investing activities | -1,406,864,147.47 | -920,040,870.59 |
| III. Cash flows from financing activities: | ||
| Cash from absorbing investments | ||
| Including: Cash from absorption of minority shareholders’ investments by subsidiaries | ||
| Cash from borrowing | 1,854,078,657.43 | 2,044,165,545.94 |
| Other cash receipts in relation to financing activities | 360,000,000.00 | 340,000,000.00 |
| Total cash inflows from financing activities | 2,214,078,657.43 | 2,384,165,545.94 |
| Cash for repayment of debt | 1,874,703,029.58 | 2,161,566,863.78 |
| Cash payments for dividends, profits or interests | 499,317,003.89 | 612,515,321.94 |
| Including: Payment of dividends and profits by subsidiaries to minority shareholders | 49,000,000.00 | |
| Other cash payments in relation to financing activities | 365,675,774.15 | 357,318,045.74 |
| Total cash outflows for financing activities | 2,739,695,807.62 | 3,131,400,231.46 |
| Net cash flows from financing activities | -525,617,150.19 | -747,234,685.52 |
| IV. Influence of exchange rate fluctuations on cash and cash equivalents | -1,383,998.81 | 4,496,816.65 |
| V. Net increase in cash and cash equivalents | 172,051,530.25 | 239,035,617.20 |
| Add: Balance of cash and cash equivalents at the beginning of the period | 3,157,407,073.26 | 2,231,771,546.50 |
| VI. Balance of cash and cash equivalents at the end of the period | 3,329,458,603.51 | 2,470,807,163.70 |
(II) Notes on adjustments of financial statements
1、Adjustments to financial statement items at the beginning of the year of the first implementation of the newaccounting standards governing leases which have been implemented since 2021
√ Applicable ?N/A
Whether any balance sheet items at the beginning of the year requires adjustment
√Yes □ No
Consolidated balance sheet
Unit: RMB yuan
| Item | December 31, 2020 | January 1, 2021 | Adjustment |
| Current assets: | |||
| Cahs and bank balances | 3,198,080,997.82 | 3,198,080,997.82 | |
| Settlement reserve | |||
| Lending to other banks and other financial institutions | |||
| Financial assets for trade | |||
| Derivative financial assets | |||
| Notes receivable | |||
| Accounts receivable | 6,137,675,568.82 | 6,137,675,568.82 | |
| Accounts receivable for financing | 828,659,217.25 | 828,659,217.25 | |
| Prepayments | 250,916,482.07 | 238,357,844.74 | -12,558,637.33 |
| Premiums receivable | |||
| Reinsurance accounts receivable | |||
| Reinsurance contract reserve receivable | |||
| Other receivables | 87,269,489.82 | 87,269,489.82 | |
| Including: Interests receivable | |||
| Dividends receivable | 4,195,666.37 | 4,195,666.37 | |
| Financial assets purchased for resale | |||
| Inventories | 4,067,635,254.80 | 4,067,635,254.80 | |
| Contract assets | |||
| Assets held for sale | |||
| Non-current assets due within one year | |||
| Other current assets | 85,654,691.58 | 85,654,691.58 |
| Total current assets | 14,655,891,702.16 | 14,643,333,064.83 | -12,558,637.33 |
| Non-current assets: | |||
| Loans and prepayments issuance | |||
| Debt investments | |||
| Other debt investments | |||
| Long-term receivables | |||
| Long-term equity investments | 850,072,053.02 | 850,072,053.02 | |
| Other equity instrument investments | 225,453,120.05 | 225,453,120.05 | |
| Other non-current financial assets | |||
| Real estate properties for investment | 17,792,735.95 | 17,792,735.95 | |
| Fixed assets | 2,420,366,582.92 | 2,420,366,582.92 | |
| Constructions in progress | 2,240,201,926.65 | 2,240,201,926.65 | |
| Biological assets for production | |||
| Oil & gas assets | |||
| Right-of-use assets | 140,149,561.51 | 140,149,561.51 | |
| Intangible assets | 1,463,242,463.99 | 1,463,242,463.99 | |
| Development expenditures | 1,469,617,262.10 | ||
| Goodwill | 1,469,617,262.10 | ||
| Long-term unamortized expenses | 8,811,339.43 | 8,811,339.43 | |
| Deferred tax assets | 137,829,774.40 | 137,829,774.40 | |
| Other non-current assets | 712,069,194.08 | 712,069,194.08 | |
| Total non-current assets | 9,545,456,452.59 | 9,685,606,014.10 | 140,149,561.51 |
| Total assets | 24,201,348,154.75 | 24,328,939,078.93 | 127,590,924.18 |
| Current liabilities: | |||
| Short-term borrowing | 1,416,932,884.87 | 1,416,932,884.87 | |
| Borrowing from the central bank | |||
| Borrowing from other banks and other financial institutions | |||
| Financial liabilities for trade | |||
| Derivative financial liabilities | |||
| Notes payable | 554,336,058.71 | 554,336,058.71 | |
| Accounts payable | 3,947,044,331.68 | 3,947,044,331.68 | |
| Receipts in Advance | 951,926.56 | 951,926.56 | |
| Contract liabilities | 94,384,629.77 | 94,384,629.77 |
| Financial assets sold for repurchase | |||
| Absorbing deposits and due from banks | |||
| Receipts for buying and selling securities as proxy | |||
| Receipts for underwriting securities as proxy | |||
| Payroll payable | 152,106,819.91 | 152,106,819.91 | |
| Taxes payable | 571,792,475.80 | 571,792,475.80 | |
| Other payables | 1,817,529,820.99 | 1,817,529,820.99 | |
| Including: Interests payable | |||
| Dividends payable | 224,219.60 | 224,219.60 | |
| Handling fees and commissions payable | |||
| Reinsurance accounts payable | |||
| Liabilities held for sale | |||
| Non-current liabilities due within one year | 67,813,886.68 | 67,813,886.68 | |
| Other current liabilities | 10,786,034.37 | 10,786,034.37 | |
| Total current liabilities | 8,633,678,869.34 | 8,633,678,869.34 | |
| Non-current liabilities: | |||
| Insurance policy reserve | |||
| Long-term borrowing | 151,611,367.86 | 151,611,367.86 | |
| Bonds payable | |||
| Including: Preferred shares | |||
| Perpetual bonds | |||
| Lease liabilities | 127,590,924.18 | 127,590,924.18 | |
| Long-term payables | 26,812,354.90 | 26,812,354.90 | |
| Long-term employee benefits payable | |||
| Estimated liabilities | 39,467,829.23 | 39,467,829.23 | |
| Deferred income | 81,628,032.54 | 81,628,032.54 | |
| Deferred tax liabilities | 88,738,187.41 | 88,738,187.41 | |
| Other non-current liabilities | |||
| Total non-current liabilities | 388,257,771.94 | 515,848,696.12 | 127,590,924.18 |
| Total liabilities | 9,021,936,641.28 | 9,149,527,565.46 | 127,590,924.18 |
| Owners’ Equity: | |||
| Share capital | 1,749,809,548.00 | 1,749,809,548.00 | |
| Other equity instruments |
| Including: Preferred shares | |||
| Perpetual bonds | |||
| Capital reserves | 2,158,080,661.07 | 2,158,080,661.07 | |
| Less: Treasury shares | |||
| Other comprehensive income | -2,191,069.45 | -2,191,069.45 | |
| Special reserve | |||
| Surplus reserves | 861,680,578.42 | 861,680,578.42 | |
| General risk reserve | |||
| Retained earnings | 9,852,441,590.56 | 9,852,441,590.56 | |
| Total owners’ equity attributable to owner of the Company | 14,619,821,308.60 | 14,619,821,308.60 | |
| Minority interest | 559,590,204.87 | 14,619,821,308.60 | |
| Total owners’ equity | 15,179,411,513.47 | 15,179,411,513.47 | |
| Total liabilities & owners’ equity | 24,201,348,154.75 | 24,328,939,078.93 | 127,590,924.18 |
Adjustment description
2、Retrospective adjustments to comparative data of the previous period due to the first implementation of the newaccounting standards leases since 2021
□ Applicable √ N/A
(III)Audit reportHas the third quarterly report been audited?
□ Yes √ No
The third quarterly report has not been audited.
The Board of Directors of Huadong Medicine Co., Ltd.
October 27, 2021